Technical Analysis for CCCC - C4 Therapeutics, Inc.

Grade Last Price % Change Price Change
D 6.04 1.17% 0.07
CCCC closed up 1.17 percent on Thursday, November 7, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Fell Below 20 DMA Bearish 1.17%
Fell Below 50 DMA Bearish 1.17%
Gapped Up Strength 1.17%
20 DMA Support Bullish -0.82%
50 DMA Support Bullish -0.82%
MACD Bullish Centerline Cross Bullish -0.82%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 6 hours ago
Possible Inside Day about 6 hours ago
Up 3% about 9 hours ago
60 Minute Opening Range Breakout about 9 hours ago
20 DMA Resistance about 10 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

C4 Therapeutics, Inc. Description

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Treatment Of Cancer Non Small Cell Lung Cancer Melanoma Colorectal Cancer Multiple Myeloma NSCLC Synovial Sarcoma Treatment Of Various Cancers Peripheral T Cell Lymphoma

Is CCCC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.88
52 Week Low 1.06
Average Volume 973,031
200-Day Moving Average 6.47
50-Day Moving Average 5.97
20-Day Moving Average 6.03
10-Day Moving Average 5.88
Average True Range 0.48
RSI (14) 51.69
ADX 16.19
+DI 22.61
-DI 15.27
Chandelier Exit (Long, 3 ATRs) 5.71
Chandelier Exit (Short, 3 ATRs) 6.40
Upper Bollinger Bands 6.79
Lower Bollinger Band 5.28
Percent B (%b) 0.5
BandWidth 24.95
MACD Line 0.01
MACD Signal Line 0.00
MACD Histogram 0.0149
Fundamentals Value
Market Cap 297.66 Million
Num Shares 49.3 Million
EPS -2.75
Price-to-Earnings (P/E) Ratio -2.20
Price-to-Sales 14.89
Price-to-Book 1.28
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.52
Resistance 3 (R3) 6.54 6.39 6.44
Resistance 2 (R2) 6.39 6.27 6.39 6.41
Resistance 1 (R1) 6.22 6.20 6.31 6.20 6.39
Pivot Point 6.07 6.07 6.12 6.07 6.07
Support 1 (S1) 5.90 5.95 5.99 5.88 5.69
Support 2 (S2) 5.75 5.88 5.75 5.67
Support 3 (S3) 5.58 5.75 5.64
Support 4 (S4) 5.56